25 Best Ways To Lose Weight That Actually Work

In This Article:

In this article, we will be taking a look at the 25 best ways to lose weight that actually work. To skip our detailed analysis, you can go directly to see 10 Best Ways To Lose Weight That Actually Work.

Obesity, a medical condition in which a person has a Body Mass Index (BMI) of 30 or more, is a significant health concern in the United States. According to data from the Centers for Disease Control and Prevention (CDC), 41.9% of adults in the country have obesity. Being overweight or obese increases the risk of developing serious health conditions like type 2 diabetes, cardiovascular disease, osteoarthritis, and some types of cancer.

As we previously reported, a survey carried out by Nutrisystem and OnePoll revealed that over 70% of Americans were now more health-conscious following the COVID-19 pandemic. 64% of those surveyed claimed their physical health had suffered since the pandemic began in March 2020, and half of them said they had gained weight in the previous two years. According to the survey, 64% of the respondents were driven to reduce their weight, considering how it had an effect on their immunity.

On the other hand, the Washington Post reports that an estimated 45 million Americans go on a diet each year. Moreover, according to a survey from KFF, nearly half of Americans are interested in taking weight-loss drugs such as such as Ozempic, Wegovy, and Mounjaro.

Ozempic and Wegovy are the two brand names that Novo Nordisk A/S (NYSE:NVO), a pharmaceutical company headquartered in Denmark, uses to market injectable semaglutide. Given that these two drugs differ in the amount of semaglutide present in them, only Wegovy, has received FDA approval for the treatment of obesity.

The maker of aforementioned drugs reported $33.7 billion in sales for 2023. Polen Global Growth Strategy stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its fourth quarter 2023 investor letter:

"As we discussed in last quarter’s commentary, Novo Nordisk A/S (NYSE:NVO) is a newer addition to the strategy. Over the fourth quarter, we continued to build the position to an average weight. As a reminder, Novo Nordisk is a global pharmaceutical company based in Denmark and has long been the leader in developing insulin for diabetes patients. In recent years, the company’s innovation into GLP-1 drugs has been shown not only to help diabetics control blood sugar levels but also to have significant efficacy in weight loss. Obesity has become a global epidemic, creating materially negative knock-on effects for humans that range from an increase in cardiovascular events and, thus, higher mortality to a lower general quality of life. We believe that, over time, payors will recognize the value of these obesity treatments to both patients and the overall healthcare system."